Gurpreet Singh focuses on design, synthesis and preclinical evaluation of small‑molecule therapeutics for metabolic, CNS and oncology indications. Work spans multi‑target ligands, kinase and GPCR antagonists, SAR, and natural‑product‑inspired scaffolds from in vitro assays to in vivo models.